What's Happening?
Amgen is seeking to rejuvenate sales of its thyroid eye disease drug, Tepezza, with a new subcutaneous formulation that has shown promising results in a phase 3 trial. The new formulation, delivered via an on-body injector, achieved a 76.7% proptosis
response rate over 24 weeks, significantly outperforming the placebo group. This development comes as Tepezza's sales have slightly declined, with a 1% dip to $457 million in the fourth quarter of 2025. Analysts suggest that the more convenient subcutaneous option could drive a commercial boost for the drug, potentially reversing the recent sales slowdown.
Why It's Important?
The introduction of a subcutaneous version of Tepezza is crucial for Amgen as it seeks to regain growth in the thyroid eye disease market. The convenience of the new formulation could enhance patient adherence and expand the drug's reach, particularly among those who find intravenous infusions burdensome. This strategic move is essential for Amgen to maintain its market position amidst increasing competition from other companies developing similar treatments. The success of this new formulation could also set a precedent for future drug delivery innovations in the pharmaceutical industry.
What's Next?
Amgen will likely focus on obtaining regulatory approvals and launching the new subcutaneous formulation of Tepezza. The company may also invest in marketing efforts to emphasize the benefits of the new delivery method. As competitors like Viridian Therapeutics advance their own TED treatments, Amgen will need to stay vigilant and possibly explore further innovations to sustain its market leadership. The outcome of these efforts will be closely watched by investors and industry analysts.
